Stifel Financial
ADAP

Stifel Financial’s Adaptimmune Therapeutics ADAP Stock Holding History

Stifel Financial’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,007
Closed -$5.52K – 3533
2025
Q2 		$5.52K Sell
23,007
-3,462
-13% -$924 ﹤0.01% 3459
2025
Q1 		$5.21K Hold
26,469
– – ﹤0.01% 3441
2024
Q4 		$14.3K Sell
26,469
-1,150
-4% -$838 ﹤0.01% 3361
2024
Q3 		$26.2K Hold
27,619
– – ﹤0.01% 3332
2024
Q2 		$26.9K Buy
27,619
+3,822
+16% +$4.19K ﹤0.01% 3311
2024
Q1 		$37.6K Sell
23,797
-3,462
-13% -$4.18K ﹤0.01% 3274
2023
Q4 		$21.6K Sell
27,259
-2,574
-9% -$1.45K ﹤0.01% 3268
2023
Q3 		$23.3K Hold
29,833
– – ﹤0.01% 3240
2023
Q2 		$27.6K Hold
29,833
– – ﹤0.01% 3267
2023
Q1 		$32.5K Sell
29,833
-850
-3% -$1.32K ﹤0.01% 3264
2022
Q4 		$44.8K Buy
30,683
+1,150
+4% +$1.86K ﹤0.01% 3196
2022
Q3 		$32K Sell
29,533
-121
-0.4% -$222 ﹤0.01% 3203
2022
Q2 		$50K Hold
29,654
– – ﹤0.01% 3229
2022
Q1 		$61K Sell
29,654
-8,500
-22% -$22.9K ﹤0.01% 3294
2021
Q4 		$143K Sell
38,154
-6,043
-14% -$27.5K ﹤0.01% 3214
2021
Q3 		$229K Buy
44,197
+848
+2% +$3.8K ﹤0.01% 3063
2021
Q2 		$185K Buy
43,349
+9,736
+29% +$47.3K ﹤0.01% 3148
2021
Q1 		$178K Buy
33,613
+2,987
+10% +$17.1K ﹤0.01% 3041
2020
Q4 		$165K Sell
30,626
-135,839
-82% -$738K ﹤0.01% 2861
2020
Q3 		$1.33M Buy
166,465
+151,031
+979% +$1.32M ﹤0.01% 1447
2020
Q2 		$154K Buy
+15,434
New +$96.9K ﹤0.01% 2645
2018
Q4 		– Sell
-90,856
Closed -$1.22M – 2658
2018
Q3 		$1.22M Buy
+90,856
New +$952K ﹤0.01% 1556

Other funds holding ADAP

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.41B AUM 41.48% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Stifel Financial's ADAP Position: Q3 2025 in Review

Stifel Financial sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 23,007 shares — an estimated $5.52K sold.

Stifel Financial first reported a position in ADAP in Q3 2018 and held it in 22 quarters. The position peaked at $1.33M in Q3 2020. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

  • Stifel Financial reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Stifel Financial sold 23,007 Adaptimmune Therapeutics shares in Q3 2025, an estimated $5.52K.
  • Stifel Financial first reported a position in Adaptimmune Therapeutics in Q3 2018 and held it in 22 quarters.
  • Stifel Financial's Adaptimmune Therapeutics position peaked at $1.33M in Q3 2020.
  • 55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on Stifel Financial's 13F filing for Q3 2025, filed 12 Nov 2025.